If you can't see this email correctly, click here.
avance logo top image
News in Avance Your Source for Valuation header 3


Alzheimer Deals

Deal terms and sales assumptions

Alzheimer's disease has suffered various late-stage set backs in the past years. Nevertheless R&D and licensing activities are ongoing because of the huge market potential if a product gets approved. We have taken a look at 21 Alzheimer deals over the last 14 years. But we haven't just listed the deals with the terms you can read out of the press releases, no, we have valued all deals and looked which deal terms and sales assumptions are most realistic.

MORE>


P U B L I C A T I O N S

Deal Terms in Alzheimer's Disease 2000 - 2014
Avance Industry Report

How To Determine Fair License Terms: No Need For Rules Of Thumb Anymore
Les Nouvelles, Licensing Executive Society

Survey about discount rates in pharma and biotech
Survey of industry professionals by Biostrat and Avance about the discount rates for biotech companies.

Valuation Book

Valuation in Life Sciences 3rd Edition
"Valuation in Life Sciences. A Practical Guide" has become the industry reference book. It has now been released already in its 3rd edition.

Click here to order.



Correlated Milestones

Simple clause, challenging to value

Milestones defined for the first, second, etc. indication or compound appear in every second license contract. In the Avance 2013 Christmas Valuation Riddle we asked you to value such an almost embarrassingly simple sounding problem. The solution is not necessarily complicated, but requires quite some thought.

MORE>


ri:val: Negotiate your deals with ri:val

ri:val has evolved from a valuation software to an important negotiation and planning tool. Clients from pharma, biotech, universities, and the investor community use ri:val to

  • Evaluate term sheets,
  • Elaborate counter-offers,
  • Read and interpret benchmark deals,
  • Value the company,
  • Run various clinical scenarios,
  • Define liquidity needs,
  • Plan resource allocation,
  • Compare different strategies.
 MORE >


You can sign up for News in Avance or change your e-mail address here.
[Abmeldelink]
Copyright: Avance, Basel GmbH - Bäumleingasse 2 - CH - 4051 Basel